Eli Lilly Expands its 2021 Agreement with ProQR Therapeutics for New Genetic Therapies
- ProQR will receive $75M upfront & equity investment, ~$3.75B in research, development & commercialization milestones along with royalties. Lilly will gain access to additional targets in CNS & peripheral nervous system with ProQR’s Axiomer platform
- Lilly to get the rights to exercise an option to expand the collaboration with $50M & may also provide ProQR with access to its delivery technology ProQR for its wholly owned pipeline. The expanded collaboration will explore applications for the platform
- The 2021 agreement focused to target disorders for the liver and nervous system using ProQR's Axiomer RNA editing platform. The new agreement supports the discovery & development of additional assets directed toward high-conviction targets using Axiomer technology
Ref: PRNewswire | Image: Eli Lilly
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.